INmune Bio Statistics
Share Statistics
INmune Bio has 22.17M shares outstanding. The number of shares has increased by 23.03% in one year.
| Shares Outstanding | 22.17M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 12.08% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 15.76M |
| Failed to Deliver (FTD) Shares | 1.58K |
| FTD / Avg. Volume | 0.64% |
Short Selling Information
The latest short interest is 3.48M, so 15.71% of the outstanding shares have been sold short.
| Short Interest | 3.48M |
| Short % of Shares Out | 15.71% |
| Short % of Float | 22.09% |
| Short Ratio (days to cover) | 14.05 |
Valuation Ratios
The PE ratio is -6.75 and the forward PE ratio is -2.77.
| PE Ratio | -6.75 |
| Forward PE | -2.77 |
| PS Ratio | 1306.22 |
| Forward PS | 4232.3 |
| PB Ratio | 5.31 |
| P/FCF Ratio | -16.9 |
| PEG Ratio | n/a |
Enterprise Valuation
INmune Bio Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 2.16, with a Debt / Equity ratio of 0.26.
| Current Ratio | 2.16 |
| Quick Ratio | 2.16 |
| Debt / Equity | 0.26 |
| Total Debt / Capitalization | 20.84 |
| Cash Flow / Debt | -1.19 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.79% and return on capital (ROIC) is -61.23%.
| Return on Equity (ROE) | -0.79% |
| Return on Assets (ROA) | -0.53% |
| Return on Capital (ROIC) | -61.23% |
| Revenue Per Employee | 14.09K |
| Profits Per Employee | -2.73M |
| Employee Count | 11 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -55.3% in the last 52 weeks. The beta is 1.85, so INmune Bio 's price volatility has been higher than the market average.
| Beta | 1.85 |
| 52-Week Price Change | -55.3% |
| 50-Day Moving Average | 5.33 |
| 200-Day Moving Average | 7.98 |
| Relative Strength Index (RSI) | 41.34 |
| Average Volume (20 Days) | 248.65K |
Income Statement
In the last 12 months, INmune Bio had revenue of $155.00K and earned -$30.01M in profits. Earnings per share was $-1.67.
| Revenue | 155.00K |
| Gross Profit | 155.00K |
| Operating Income | -29.74M |
| Net Income | -30.01M |
| EBITDA | 0 |
| EBIT | -29.74M |
| Earnings Per Share (EPS) | -1.67 |
Balance Sheet
The company has $35.85M in cash and $10.44M in debt, giving a net cash position of $25.41M.
| Cash & Cash Equivalents | 35.85M |
| Total Debt | 10.44M |
| Net Cash | 25.41M |
| Retained Earnings | -121.02M |
| Total Assets | 52.78M |
| Working Capital | 22.03M |
Cash Flow
In the last 12 months, operating cash flow was -$11.98M and capital expenditures $0, giving a free cash flow of -$11.98M.
| Operating Cash Flow | -11.98M |
| Capital Expenditures | 0 |
| Free Cash Flow | -11.98M |
| FCF Per Share | -0.67 |
Margins
Gross margin is 100%, with operating and profit margins of -19.19K% and -19.36K%.
| Gross Margin | 100% |
| Operating Margin | -19.19K% |
| Pretax Margin | -19.36K% |
| Profit Margin | -19.36K% |
| EBITDA Margin | 0% |
| EBIT Margin | -19.19K% |
| FCF Margin | -7.73K% |
Dividends & Yields
INMB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -35.01% |
| FCF Yield | -11.32% |
Analyst Forecast
The average price target for INMB is $21, which is 340.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $21 |
| Price Target Difference | 340.3% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -2.37 |
| Piotroski F-Score | 2 |